Tumour targeting and radiation dose of radioimmunotherapy with $^{90}$Y-rituximab in CD20+ B-cell lymphoma as predicted by $^{89}$Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab

Kristoff Muylle · Patrick Flamen · Danielle J. Vugts · Thomas Guiot · Ghanem Ghanem · Nathalie Meuleman · Pierre Bourgeois · Bruno Vanderlinden · Guus A. M. S. van Dongen · Hendrik Everaert · Mélanie Vaes · Dominique Bron

Received: 15 October 2014 / Accepted: 19 February 2015 / Published online: 20 March 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Purpose To compare using immuno-PET/CT the distribution of $^{89}$Zr-labelled rituximab without and with a preload of unlabelled rituximab to assess the impact of preloading with unlabelled rituximab on tumour targeting and radiation dose of subsequent radioimmunotherapy with $^{90}$Y-labelled rituximab in CD20+ B-cell lymphoma.

Methods Five patients with CD20+ B-cell lymphoma and progressive disease were prospectively enrolled. All patients underwent three study phases: initial dosimetric phase with baseline $^{89}$Zr-rituximab PET/CT imaging without a cold preload, followed 3 weeks later by a second dosimetric phase with administration of a standard preload (250 mg/m$^2$) of unlabelled rituximab followed by injection of $^{89}$Zr-rituximab, and a therapeutic phase 1 week later with administration of unlabelled rituximab followed by $^{90}$Y-rituximab. PET/CT imaging and tracer uptake by organs and lesions were assessed.

Results With a cold rituximab preload, the calculated whole-body dose of $^{90}$Y-rituximab was similar (mean 0.87 mSv/MBq, range 0.82–0.99 mSv/MBq) in all patients. Without a preload, an increase in whole-body dose of 59 % and 87 % was noted in two patients with preserved circulating CD20+ B cells. This increase in radiation dose was primarily due to a 12.4-fold to 15-fold higher dose to the spleen without a preload. No significant change in whole-body dose was noted in the three other patients with B-cell depletion. Without a preload, consistently higher tumour uptake was noticed in patients with B-cell depletion.

Conclusion Administration of the standard preload of unlabelled rituximab impairs radioconjugate tumour targeting in the majority of patients eligible for radioimmunotherapy, that is patients previously treated with rituximab-containing therapeutic regimens. This common practice may need to be reconsidered and further evaluated as the rationale for this high preload has its origin in the “prerituximab era”.

Clinical Trial Application: CTA 2011-005474-38
Trial Registry: EudraCT

Keywords Radioimmunotherapy · CD20+ B-cell lymphoma · $^{90}$Y-Rituximab ·
Rituximab preload · Immuno-PET · $^{89}$Zr-rituximab · Dosimetry

**Introduction**

Radioimmunootherapy (RIT) is the targeting of a monoclonal antibody (mAb) coupled to a radioisotope to selectively deliver ionizing radiation to tumours [1]. As lymphoma cells are inherently radiosensitive, the CD20 antigen provides an excellent target for RIT because it is expressed at a high surface density in most lymphomas [2]. Following RIT, both malignant and normal B cells are depleted, with normal B cells recovering within 6 months [3].

The most widely studied radioconjugates for the treatment of B-cell non-Hodgkin’s lymphoma (NHL) are murine anti-CD20 mAbs radiolabelled with $^{131}$I (tositumomab, Bexxar®; GlaxoSmithKline, Brentford, UK; no longer available) or with the pure β-emitting isotope $^{90}$Y (ibritumomab tiuxetan, Zevalin®; Spectrum Pharmaceuticals Inc., Henderson, NV). In Europe, only $^{90}$Y-ibritumomab has been licensed, and it is used in combination with a preload of unlabelled rituximab [4]. Several studies have shown the efficacy of RIT in patients with CD20+ B-cell NHL, both as a single agent in indolent lymphoma and in combination with chemotherapy in indolent and aggressive lymphoma [3, 5–9]. Recently, the feasibility of RIT with $^{90}$Y-rituximab using a $^{90}$Y-ibritumomab treatment schedule has been reported [10].

As normal tissue toxicity (particularly myelosuppression) is dose limiting for RIT, the therapeutic index for RIT is thought to be enhanced by the use of excess unlabelled (“cold”) antibodies before RIT [2]. Preloading with unlabelled antibodies is thought to prevent normal tissue toxicity by providing a more predictable biodistribution profile of radiolabelled antibodies, decreasing clearance rates and prolonging the circulating half-life of the radiolabelled antibody [1, 11–13]. This preload is assumed to clear the peripheral blood of B cells and enhance targeting of the radiolabelled antibody to tumour cells. Despite the common use of a preload of unlabelled antibodies before RIT [14, 15], including its inclusion in clinical guidelines [4], little is known about the potential impact of high levels of circulating anti-CD20 antibodies on the targeting of a subsequent radiolabelled anti-CD20 antibody.

The further refinement of RIT has evolved to include consideration of the use of immuno-PET technology in its application [16]. Immuno-PET, the combination of PET and a radiolabelled mAb, combines the high sensitivity and resolution of a PET camera with the specificity of a mAb [17, 18]. PET is better suited than SPECT to tracer quantification [17], while targeting information can be combined with anatomical information when PET/CT is used [19]. Apart from its diagnostic capabilities and use in treatment planning, immuno-PET has potential for quantification of molecular interactions, which is particularly attractive when it is used for simulation of subsequent antibody-based therapy.

The majority of available PET isotopes are not appropriate for routine PET imaging because of unsuitable half-lives, poor availability, high production costs, and poorly developed radiochemistry [18]. $^{89}$Zr, which is a transition metal in group IVB of the periodic table, decays by positron emission (fraction 23 %) and electron capture (77 %) to $^{89}$Y. The concomitant gamma decay of $^{89}$Zr of 908.97 keV has no significant influence on the quantitative accuracy of PET images because these high-energy photons, with an energy far exceeding 511 keV, can be easily circumvented by the energy window of the PET scanner. $^{89}$Zr has a half-life of 78.4 h, which is compatible with the time needed for a mAb to achieve optimal tumour-to-background ratios. $^{89}$Zr can be obtained in high yield and radionuclide purity, and with low production costs. Moreover, $^{89}$Zr has ideal characteristics for optimal image quality and accurate quantification.

In what we believe to be the first report of the use of $^{89}$Zr-rituximab, the aim of this study was to compare the distribution of $^{89}$Zr-rituximab with and without a standard preload of unlabelled rituximab in patients with relapsed CD20+ B-cell lymphoma, with the aim of assessing the potential impact of circulating anti-CD20 antibodies on whole-body distribution, radiation dose and tumour targeting of a subsequent radiolabelled anti-CD20 antibody as part of a RIT regimen.

**Materials and methods**

Radioconjugate production

$^{89}$Zr-Rituximab was produced in a Good Manufacturing Practice facility with a manufacturing license at the VU/VUmc campus (Amsterdam, Netherlands). $^{89}$Zr (2.7 GBq/mL in 1 M oxalic acid) was produced by the BV cyclotron using a (p,n) reaction on natural $^{88}$Y and isolated using a hydroxamate column. The starting point of the chelator was desferrioxamine B (Desferal®; Novartis Pharma Stein AG, Stein, Switzerland), which was converted to its succinylated form, N-succinyl-desferrioxamine B (N-sucDF). The hydroxamate groups of N-sucDF are temporarily blocked with iron [Fe(III)], and the N-sucDF-Fe form was esterified with 2,3,5,6-tetrafluorophenol (TFP) to the bifunctional chelator, TFP-N-sucDF-Fe. Rituximab (Mabthera®; Roche, Basel, Switzerland) was labelled with $^{89}$Zr starting from the chelate, TFP-N-sucDF-Fe, as described previously [20]. In brief, rituximab was modified by coupling of a Fe-N-sucDF-TFP ester at room temperature (pH 9.5–9.7). The iron was then removed from the chelate with an excess of ethylenediaminetetraacetic acid at 35 °C (pH 4.2–4.5), and the modified protein was purified on a pyrogen-free PD-10 column. The modified rituximab...
was labelled with $^{89}$Zr by first neutralizing the pH of the $^{89}$Zr solution with sodium carbonate and the protein was added together with 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid buffer. After 60 min, the $^{89}$Zr-labelled protein was purified on a pyrogen-free PD-10 column, and the product filtered. The immunoreactivity of $^{89}$Zr-rituximab was evaluated using a Lindmo cell binding assay [21], using 0.1 % paraformaldehyde-fixed NHL RAMOS cells, with an immunoreactive fraction above 70 % for each individual labelling procedure.

Study population

Five patients with CD20+ B-cell lymphoma and progressive disease, and at least one prior treatment regimen were enrolled. Treatment with rituximab had to be stopped at least 6 months before inclusion.

Methodology

The study comprised three phases:

1. Diagnostic/dosimetric phase I: Baseline $^{89}$Zr-rituximab dynamic PET/CT imaging after injection of $^{89}$Zr-rituximab (111 MBq) without a preload of unlabelled rituximab.
2. Diagnostic/dosimetric phase II (3 weeks later): Administration of a standard preload (250 mg/m$^2$) of unlabelled rituximab followed 1 to 3 h later by injection of $^{89}$Zr-rituximab and dynamic PET/CT imaging.
3. Therapeutic phase (1 week later): Administration of 250 mg/m$^2$ of unlabelled rituximab followed by slow intravenous injection of $^{90}$Y-rituximab, using the same doses as recommended for treatment with $^{90}$Y-ibritumomab tiuxetan (Zevalin®; 0.3 mCi/kg, 11.1 MBq/kg, if platelet count $100,000$ to $150,000$/mm$^3$, 100 to $150 \times 10^9$/L; and 0.4 mCi/kg, 14.8 MBq/kg, if platelet count $>150 \times 10^9$/L) [4].

PET/CT imaging

PET/CT scans were performed with a dedicated BGO PET system coupled to a helical CT scanner (Discovery LS; GE Healthcare Technologies, Milwaukee, WI), and PET/CT images were visualized on a dedicated viewing station (Advantage Windows 4.5; GE).

$^{89}$Zr-rituximab

Whole-body PET scans consisting of seven or eight bed positions covering the patient from the base of the skull to the upper thighs were obtained. At each bed position, a 5-min emission scan in three-dimensional mode was acquired. Whole-body scans were completed at three time-points starting within 1 h and at 72 h and 144 h after the first intravenous injection of 111 MBq $^{89}$Zr-rituximab. All scans were normalized and corrected for randoms, scatter, attenuation and decay. The images (matrix $128 \times 128$) were reconstructed using an attenuation and a normalization-weighted ordered subsets expectation maximization (OSEM) algorithm (Advance 6.0), with five iterations and 32 subsets followed by postsmoothing of the reconstructed images using an 8-mm full-width at half-maximum Gaussian filter.

CT scan

CT was performed in all patient studies at “low dose”, without administration of oral or intravenous contrast agent. The tube current intensity used by the CT scanner was determined by Auto-mA®, a dose-reduction algorithm provided by the camera vendor that modulates the tube current intensity during acquisition depending on a noise index and the attenuation information given by the planar scout image. The noise index for low-dose CT scans was 28. The current intensity ranged from 30 to 200 mA, and the voltage was set to 120 kV. The whole-body absorbed dose for the CT scans ranged between 3 and 5 mSv. The CT map was used for attenuation correction of the PET scans and as a structural correlate to optimize PET image interpretation.

Contouring

Organs were contoured on the anatomical images obtained from the CT scans using the DosiSoft® station. PET/CT coregistration was checked visually. The contours were then projected on the PET images for statistical analysis. The considered organs (for which residence times were calculated) were the liver, spleen, bone marrow (skeleton), kidneys, lungs, gonads and thyroid. The activity for calculating the residence times for the remainder of the body was obtained from whole-body (head to thigh) volumes of interest (VOIs), minus the sum of the activities of the considered organs. The bone marrow activity was assessed by automatic segmentation of the skeleton (excluding the skull) performed on CT images using OWS® 1.0.

Several contouring methods were applied for the lesions due to the great variability in visibility, both on CT and PET images. When lesions were identifiable on PET images (i.e. with an activity concentration higher than background activity), lesions were segmented with a fixed threshold of 42 % of the maximum activity value. When there was an overlap between lesions, the CT images helped discriminate the different lesions. When lesions were not identifiable on PET or automated segmentation was not reliable (i.e. because the contrast was too low or because of proximity to organs with high uptake), two options were possible: (1) if the lesion was clearly identifiable on CT images, contours were drawn on the CT images and then projected on the PET images; and (2) if the lesion was not clearly identifiable on CT images, contours were drawn on the day-6 PET images (where lesion contrast
was often the highest) using the method described above, and earlier PET images were then registered on the day-6 images and the contours were projected, and manual corrections were applied if registration was imperfect.

Quantification

The contours were exported in RT Structure format, then imported into PMOD (PMOD Technologies Ltd, Zürich, Switzerland) for quantification. The total activity (average activity in a VOI multiplied by the volume) measured by PMOD was divided by the injected activity (with decay correction) resulting in the uptake percentage of organs and lesions.

Dosimetry

Dosimetry was performed using OLINDA/EXM®. For $^{89}$Zr dosimetry, the time–activity curve (TAC) was plotted using the activity values given by PMOD. For $^{90}$Y dosimetry, the activity values were calculated from the $^{89}$Zr activities according to the equation:

$$A_{90Y}(t_{acq}) = A_{89Zr}(t_{acq}) \times e^{\ln(2) \times \left(\frac{t_{acq} - t_{inj}}{t_{90Y}} - \frac{t_{inj}}{t_{89Zr}}\right)}$$

Where $A_{90Y}(t_{acq})$ and $A_{89Zr}(t_{acq})$ are the activities calculated and measured, respectively, at the different acquisition times, $t_{inj}$ is the time of injection and $t_{89Zr}$ and $t_{90Y}$ are the half-lives of the isotopes.

The total area under the TAC was calculated by summing the following areas, with the following approximations: (1) the area for the interval between time zero (injection) and time 1 (1 h after injection) calculated using a rectangle; (2) the area between the three acquisition time-points calculated using trapezoids between each time-point; and (3) the area after the third time-point calculated using the physical decay. The total area under the curve was then divided by the injected activity (at time zero) to give the time-integrated activity coefficient, which was inputted into OLINDA/EXM® (residence times for each considered organ are available in the Supplementary Online Table 1).

Results

Patient characteristics are shown in Table 1. Five patients with CD20+ B-cell lymphoma with progressive disease and who had at least one prior treatment regimen were enrolled. Four patients were treated for a relapse of follicular lymphoma and one for a nodular lymphocyte-predominant, CD20+ Hodgkin’s lymphoma. None of the patients had bone marrow involvement. The median age of the patients was 51 years.
(range 41–62 years) and all were male. The median number of previous treatment lines was three (range one to four). The two patients with fewer than three previous treatments (patients 1 and 2) had preserved circulating CD20+ lymphocytes (assessed by immunophenotyping in the blood before inclusion in this study), while the other three patients had B-cell depletion (patients 3, 4 and 5) due to three or more prior treatment lines (although immunophenotyping was not available for patient 4, this patient was considered to have B-cell depletion having been previously treated with autologous stem cell transplantation and RIT). A detailed overview of the effective and absorbed doses for 89Zr-rituximab and 90Y-rituximab is available in the Supplementary Online Tables 2–5.

With a preload of unlabelled rituximab, the calculated effective (whole-body) doses for 90Y-rituximab were similar in all patients (mean 0.87 mSv/MBq, range 0.82–0.99 mSv/MBq). Without a preload, the whole-body radiation doses were 59 % and 87 % higher than with a preload in patients 1 and 2, respectively, but were not significantly different in the three other patients (Fig. 1).

The higher whole-body radiation doses without a preload in patients 1 and 2 were primarily due to higher radiation doses to the spleen (Fig. 2). Without a preoad of rituximab, the uptake of the radioconjugate, 90Y-rituximab, was 12.4-fold to 15-fold higher in these two patients and only 1.1-fold to 2.4-fold higher in the other three patients. Correlation with the number of previous treatment lines in each patient showed that the higher tracer uptake in the spleen, and hence the higher whole-body radiation dose, was much higher in the two patients who had had only one or two previous treatment regimens, and was only moderately higher in the three patients who had three or four previous treatment regimens. Correlation of the percentage of circulating B cells revealed that the influence of a preload of rituximab on the distribution of the radioconjugate, especially uptake in the spleen, depended highly on the amount of uptake of circulating CD20+ lymphocytes in the spleen (Fig. 3). A major influence of the preload is noted in the two patients with preserved (5–9 %) circulating CD20+ lymphocytes, while only a minor influence on the radiation dose to the spleen was seen in patients with B-cell depletion (0 % circulating CD20+ lymphocytes).

Without a preoad, the radiation doses to the bone marrow in patients 1 and 2 were primarily due to higher radiation doses to the spleen (Fig. 2). Without a preload, the radiation doses to the spleen were 9 % to 58 % higher than with a preload (Fig. 4), while the radiation doses to the liver were similar with and without a preload (Fig. 5).

For 89Zr-rituximab, the calculated effective (whole-body) doses after a preload of unlabelled rituximab were similar in all patients (mean 0.41 mSv/MBq, range 0.39–0.44 mSv/MBq). Without a preload, the whole-body radiation doses were 37 % and 55 % higher than with a preload in the two patients with preserved circulating CD20+ lymphocytes, primarily due to higher radiation doses to the spleen, but were not significantly different in the three patients with B-cell depletion (Table 2).

Comparison of the maximum standardized uptake value (SUVmax) of the 30 lesions in the five patients (Fig. 6) using the 89Zr-rituximab immuno-PET/CT images taken 6 days after injection showed a consistently higher lesion uptake (tumour targeting) without a preload in all three patients with B-cell depletion (as illustrated in patient 4 in Fig. 7). In the two patients with preserved circulating CD20+ lymphocytes, three lesions showed less or no uptake without a preload, while other lesions showed higher uptake. A more detailed evaluation of these three lesions with low uptake revealed the reasons for this finding. In patient 1 (with 9 % circulating CD20+ lymphocytes) with the preload, uptake in an involved lymph node was higher as a result of lower uptake in the spleen leading to a higher residence time of the tracer in the blood circulation. Images obtained without the preload showed intense uptake in the spleen and fast clearance of the injected tracer from the blood 1 h after 89Zr-rituximab injection (Fig. 8). In patient 2 (with 5 % circulating CD20+ lymphocytes) with the preload, tracer uptake in involved lymph nodes was lower on the one hand, but on the other hand was higher in the two visceral lesions as a result of lower uptake in the spleen leading to a higher residence time of the tracer in the blood circulation and binding of the radioconjugate in less
accessible regions (Fig. 9). The pharmacokinetics of $^{89}$Zr-rituximab confirmed the fast clearance of $^{89}$Zr-rituximab from the blood in both patients (particularly patient 1) with preserved circulating CD20+ lymphocytes without preload and the significantly slower clearance of the radioconjugate (comparable with the clearance in patients with B-cell depletion) with a preload (Fig. 10).

Discussion

The efficacy of RIT in patients with B-cell NHL as a single agent in indolent lymphoma and in combination with chemotherapy in both indolent and aggressive lymphoma has been reported [3, 5–9]. The anti-CD20 antibodies, $^{90}$Y-ibrutinomab tiuxetan and $^{131}$I-tositumomab, are the only radiolabelled antibodies licensed for RIT, with $^{90}$Y-ibrutinomab tiuxetan being currently the only commercially available agent.

There is interest in developing a RIT regimen incorporating radiolabelled rituximab, which is part of the standard of care in NHL [22–25]. Rituximab is a chimeric IgG1 kappa mAb targeting the same epitope on the CD20 antigen as the murine mAb ibrutinomab, and which is predicted to increase immune-based antitumour activity, improve pharmacokinetics and reduce immunogenicity compared to currently available radioconjugates. RIT with $^{90}$Y-rituximab in CD20+ B-cell lymphoma has shown promising efficacy and tolerability when utilizing the $^{90}$Y-ibrutinomab tiuxetan schedule [10].

The efficacy of RIT is dependent on the properties of the targeted antigen (i.e. specificity, tumour selectivity, density, availability, shedding, heterogeneity of expression), the properties of the tumour (i.e. vascularization, blood flow, permeability), the properties of the antibody, and the properties of the radioisotope (i.e. emission characteristics, half-life, bioavailability) [14, 26]. The therapeutic index of RIT is thought to be improved if it is preceded by administration of excess cold antibodies that prolongs the circulating half-life of the radiolabelled antibody and blocks nonspecific binding to normal tissues resulting in increased tumour retention of the radiolabelled antibody [12, 14].

Despite the common use of a preload of cold antibodies before RIT [4], little is known about the potential impact of such high levels of circulating anti-CD20 antibodies on tumour targeting of a subsequently administered radiolabelled anti-CD20 antibody. This common practice is based on a
small phase 1\/2 dosimetry study using $^{111}$In-labelled ibritumomab tiuxetan planar imaging in six patients [27]. In three of these patients, a preload of 100 mg\!/m$^2$ rituximab was administered, while the other three patients received 250 mg\!/m$^2$. The 250 mg\!/m$^2$ rituximab dose was chosen as the dose to be given before RIT because no difference in imaging or dosimetry was observed between dosing groups, and there was potential for enhanced clinical response from the higher dose of rituximab. However, no comparison has been made on the distribution without a predose of unlabelled antibodies. Furthermore, the study evaluated the impact of a preload with chimeric antibodies (rituximab) on targeting of a second radiolabelled murine anti-CD20 antibody (ibritumomab).

To the best of our knowledge, our study is the first to compare the distribution of $^{89}$Zr-rituximab with and without a standard preload of unlabelled antibodies. Furthermore, the study evaluated the impact of a preload with chimeric antibodies (rituximab) on targeting of a second radiolabelled murine anti-CD20 antibody (ibritumomab).

Table 2  Absorbed doses to the liver, spleen and red marrow, and effective whole-body dose for $^{89}$Zr-rituximab

|                         | Without preload | With preload | Mean±SD | Mean±SD |
|-------------------------|-----------------|--------------|---------|---------|
| **Liver (mGy/MBq)**     | 1.13            | 0.86         | 0.89    | 0.55    |
|                         | 1.21            | 0.62         | 0.62±0.11|
| **Red marrow (mGy/MBq)**| 0.59            | 0.59         | 0.50    | 0.54    |
|                         | 0.62±0.11       | 0.53         | 0.53    | 0.53    |
| **Spleen (mGy/MBq)**    | 12.30           | 0.98         | 0.89    | 1.10    |
|                         | 0.92            | 0.65         | 0.93    | 0.53    |
| **Whole body (mSv/MBq)**| 0.68            | 0.41         | 0.40    | 0.44    |
|                         | 0.43            | 0.42         | 0.42    | 0.39    |

Fig. 6  Comparison of lesion uptake ($SUV_{\text{max}}$) without and with a preload of unlabelled rituximab

Lesion uptake ($SUV_{\text{max}}$) without versus with a preload of unlabelled antibodies

The influence of the standard preload dose of unlabelled rituximab (250 mg\!/m$^2$) between patients with and without B-cell depletion were observed. In patients with B-cell depletion, which represents the majority of patients currently treated with RIT, the preload of unlabelled rituximab had no significant influence on whole-body radiation dose, yet consistently impaired tumour targeting due to a partial saturation of CD20 receptors present on lymphoma cells. In contrast, in the two patients with preserved circulating CD20+ lymphocytes, the preload of unlabelled rituximab cleared circulating B lymphocytes from the blood, reduced whole-body radiation dose, significantly reduced radioactivity uptake in the spleen, and resulted in slower clearance of the radioconjugate from the circulation.

The preload of cold rituximab consistently impaired tumour targeting in the three patients with B-cell depletion. In contrast, it had a variable influence on tumour targeting in the two patients with preserved circulating CD20+ lymphocytes,
enhancing uptake in three lesions (of which two were visceral) by improving biodistribution and preventing sequestration of the radioconjugate by the antigen sink, while impairing targeting of other tumour sites due to partial saturation with unlabelled rituximab.

Although clinical studies have shown that high and even multiple doses of induction therapy with rituximab alone or as part of rituximab-containing chemotherapy regimens do not appear to compromise the clinical efficacy of subsequent anti-CD20-based RIT [28–30], and that high serum levels of rituximab significantly increase the effective half-life of subsequent radionuclide labelled rituximab [29], the key issue of the optimal treatment approach for RIT remains to be elucidated. New treatment approaches, such as fractionated RIT [29, 31] or dual-targeted antibody/radioantibody therapy [32], have the potential to further improve the clinical efficacy of RIT. A recent phase I study [33] has shown encouraging results in patients with relapsed/refractory aggressive lymphoma using a fractionated dosing schedule along with the dual-targeting approach with the intention of improving the delivery and retention of the radioconjugate at the tumour sites. In that study, unlabelled anti-CD20 veltuzumab was administered to deplete the circulating B cells, enhancing biodistribution of the anti-CD22 radioconjugate ⁹⁰Y-epratuzumab tetraxetan without interfering with tumour targeting.

The inherent heterogeneity of radiopharmaceutical distribution in target lesions and normal organs suggests that a individualized patient-tailored approach might be of additional value in RIT. The antigen sink, which depends on several parameters such as tumour burden, spleen volume and amount of circulating B-lymphocytes, plays a key role in the amount of rituximab needed to ensure adequate serum levels (effective half-life) of the radioconjugate. Other factors influencing

---

**Fig. 7** ⁸⁹Zr-rituximab immuno-PET/CT images in patient 4 (with CD20+ B-cell depletion) obtained 6 days after injection without and with a preload of unlabelled rituximab show consistently better tumour targeting without the preload.

**Fig. 8** ¹⁸F-FDG PET and ⁸⁹Zr-rituximab immuno-PET images in patient 1 obtained 1 h after injection and 6 days after injection without a preload of unlabelled rituximab and 6 days after injection with a preload of unlabelled rituximab show higher uptake in the involved lymph node with the preload as a result of a higher residence time of the tracer in the blood circulation.

**Fig. 9** ¹⁸F-FDG PET/CT and ⁸⁹Zr-rituximab immuno-PET/CT images in patient 2 obtained 6 days after injection with and without a preload of unlabelled rituximab show lower tracer uptake in involved lymph nodes with the preload (white arrows), but higher uptake in less accessible visceral lesions (oesophagus and stomach; blue arrows) resulting in better tumour targeting.
tumour targeting by the radioconjugate are tumour heterogeneity and site of tumour involvement. Adequate receptor imaging might be a promising tool for the evaluation of the influence of these multiple factors on tumour targeting, for imaging-based three-dimensional calculation of the absorbed dose for organs and lesions, and for simulation of different treatment approaches. In the five patients in this study a pre-load of rituximab improved the biodistribution of the radioconjugate by preventing its sequestration in patients with preserved circulating CD20+ lymphocytes, but consistently impaired radioconjugate tumour targeting in patients with B-cell depletion, the latter representing the majority of patients eligible for RIT in the “rituximab era”. However, the small number of patients in this study along with the multiple parameters influencing tumour targeting in RIT in CD20+ lymphoma do not allow drawing definitive conclusions concerning the optimal treatment approach in RIT to be drawn, and this should be the basis of further studies.

The advantage of using a positron-emitting isotope is that PET is inherently quantitative, whereas quantification with planar imaging involves considerable uncertainties that can often be greater than estimated activity concentrations. $^{89}$Zr-rituximab PET/CT, as assessed in our study, provides an excellent imaging tool for accurate quantification of CD20 antigen expression, which is of particular interest for dosimetry as a prelude to RIT with $^{90}$Y-rituximab, allowing the possibility for dose–response correlation, prediction of treatment outcome, better selection of patients for receptor-targeted therapy, and patient-tailored image-guided therapy [17, 34–36].

The effective patient dose of $^{89}$Zr-rituximab (after a preload of unlabelled rituximab) was relatively high (0.41 mSv/MBq), probably due to the long half-life of the tracer and concomitant gamma decay of $^{89}$Zr of 908.97 keV. In this study we administered 111 MBq $^{89}$Zr-rituximab that resulted in an average total effective dose of 45.5 mSv, which is justifiable within the context of subsequent RIT with administration of 14.8 MBq/kg of $^{90}$Y-rituximab (1,184 MBq for a body weight of 80 kg), resulting in an average total effective dose of 1.03 Sv for RIT. Nevertheless, given the high image quality with 111 MBq in this study and the high sensitivity of new-generation (time-of-flight) PET scanners, lowering the injected activities to 74 MBq (or less by increasing the acquisition time, especially on day 6 after injection) while preserving the largely sufficient quantitative image accuracy should be feasible.

As there are currently no dosimetry data available for $^{90}$Y-rituximab, the doses were compared with those of $^{90}$Y-ibritumomab (after a preload of rituximab) for selected organs using $^{89}$Zr-immuno-PET.

### Table 3

Comparison of doses of $^{90}$Y-rituximab and $^{90}$Y-ibritumomab (after a preload of rituximab) for selected organs using $^{89}$Zr-immuno-PET

| Study            | Radioconjugate | Absorbed organ doses (mGy/MBq, mean±SD) | Effective whole-body dose (mSv/MBq, mean±SD) |
|------------------|----------------|-----------------------------------------|---------------------------------------------|
|                  |                | Liver | Spleen | Kidneys | Lungs | Red marrow |                                                |
| Current study    | $^{90}$Y-Rituximab | 2.28±0.31 | 2.02±1.01 | 2.24±0.30 | 2.18±0.16 | 1.49±0.16 | 0.87±0.07 |
|                  |                | (2.09–2.82) | (1.14–3.40) | (1.75–2.54) | (1.92–2.35) | (1.28–1.73) | (0.82–0.99) |
| [34]             | $^{90}$Y-Ibritumomab | 3.2±1.8 | 2.88±0.67 | 1.46±0.31 | 1.47±0.34 | 0.52±0.04 | 0.87±0.14 |
|                  |                | (1.5–6.6) | (1.83–3.83) | (0.99–1.88) | (1.07–1.82) | (0.48–0.58) | (0.70–1.06) |
Emitted by 90Y is limited to the organ only. The mean absorbed doses of 90Y-epitope) [34], both after a preload of rituximab and using 89Zr-/90Y-ibritumomab study, the mean absorbed dose of 90Y-ibritumomab in the liver and spleen tend to be higher and those for kidneys and lungs somewhat lower (Table 3). The mean absorbed dose of 90Y-rituximab to the red marrow was threefold higher. Although some differences in pharmacokinetics between the two mAbs may be expected, it is more likely that the discrepancy in the absorbed doses are due to differences in methodology between studies. The major difference in methodology is for the assessment of the dose to the red marrow. In the current study, a novel three-dimensional image-based approach was used for assessing the bone marrow dose, while for the 89Zr-/90Y-ibritumomab study, red marrow dosimetry was based on blood samples, where the residence time was estimated assuming a red marrow radioactivity concentration of 30% of the whole-blood activity concentration [37]. The latter approach may underestimate the red marrow dose if there is any interaction of the targeting agent with the bone marrow.

The similar haematological toxicities (and efficacy) after 90Y-rituximab (using the Zevalin® treatment schedule) in the present study (Table 1) and a previous study [10] support the assumption that the threefold higher mean absorbed dose of 90Y-rituximab to the red marrow compared to that of 90Y-ibritumomab was more likely due to differences in methodology than to higher accumulation of the chimeric radioconjugate in the bone marrow. Another difference in methodology between the two studies is that the organ VOIs in the current study were drawn on the anatomical images obtained from the coregistered CT images (using PET/CT), while in the 89Zr-/90Y-ibritumomab study the images were acquired on a stand-alone PET scanner with the organs contoured on functional images. Finally, in the current study, whole-body VOIs (not including part of the legs) were used for calculating the residence times for the remainder of the body, that somewhat underestimated the effective whole body doses. However, this would not have affected the calculated absorbed organ doses of 90Y-rituximab, as the deposition of the energy of the radiation emitted by 90Y is limited to the organ only.

In conclusion, the results of our study show that the administration of the standard preload of unlabelled rituximab impairs tumour targeting of the radioconjugate in the majority of patients eligible for RIT, primarily patients with B-cell depletion due to prior treatment with rituximab-containing therapeutic regimens. As the rationale for this high pre dose has its origin in the “prerituximab era”, this common practice may need to be reconsidered and further evaluated, in particular in the different setting of the licensed radioconjugate 90Y-ibritumomab tiuxetan (Zevalin®), where a chimeric antibody (rituximab) is used as a preload for subsequent RIT with a second radio labelled murine anti-CD20 antibody (ibritumomab). Our observations also suggest that imaging with a mAb labelled with a positron-emitting isotope, such as 89Zr, in combination with PET could be useful for visualizing the biodistribution of the individual radiotracer, and may have utility in the elucidation of the dose–response of RIT and in defining patients at high risk of toxicity. Further investigation is warranted to confirm the potential role of immuno-PET in receptor-targeted therapies.

Acknowledgments This work was supported by the Belgian National Cancer Plan, Télévie/Fond de la Recherche Scientifique (FNRS) and Les Amis de l’Institut Bordin (AIB). The authors thank In Vivo Communications for editorial assistance in the preparation of this manuscript.

Compliance with ethical standards
Conflicts of interest None.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References
1. Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med. 2008;49:674–8.
2. Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med. 2003;44:437–45.
3. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63.
4. Tennvall J, Fischer M, Bischof Delaloye A, Bombardieri E, Bodei L, Giammarile F, et al. EANM procedure guideline for radioimmunotherapy for B-cell lymphoma with 90Y-radio labelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616–22.
5. Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsiovics T, Kosinski M, et al. Long-term complete responses after 131I-
tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer. 2006;94:1770–6.
6. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Finn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 tositumomab tixetan. Cancer. 2007;109:1804–10.
7. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–9.
8. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:413–9.
9. Hagenbeek A, Bischof Delaloye A, Radford JA, Rohatiner A, Salles G, Van Hoof A, et al. 90Y-tositumomab tixetan (Zevalin®) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 patients. Blood. 2007;110:643 (abstract).
10. Vaes M, Bron D, Vugts DJ, Paesmans M, Meuleman N, Ghanem G, et al. Safety and efficacy of radioimmunotherapy with 90Yttrium-rutixumab in patients with relapsed CD20+ B cell lymphoma: a feasibility study. J Cancer Sci Ther. 2012;4:394–400.
11. Wahl RL, Zasadny KR, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med. 1998;39:21S–7S.
12. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res. 1992;52:637–42.
13. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1999;339:459–65.
14. Ivanov A, Swann R, Illidge T. New insights into the mechanisms of action of radioimmunotherapy in lymphoma. J Pharm Pharmacol. 2008;60:987–98.
15. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003;30:31–8.
16. Boerman OC, Oyen WJ. Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med. 2011;52:1171–2.
17. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46 Suppl 1:164S–71S.
18. Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. Curr Radiopharm. 2011;4:131–9.
19. International Atomic Energy Agency. The role of PET/CT in radiation treatment planning for cancer patient treatment (IAEA-TECDOC-1603). Vienna: IAEA; 2008.
20. Verel I, Visser GW, Boellaard R, Stigtger-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271–81.
21. Lindmo T, Boven E, Luttita F, Fredorko J, Bunn Jr PA. Determination of the immunoreactive fraction of radiolabeled antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89.
22. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579–86.
23. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
24. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.
25. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmitz, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.
26. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol. 2000;10:73–93.
27. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/I trial of I DEC YZB8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793–803.
28. Jacobs SA, Swerdlov SH, Kant J, Foon KA, Jankowitz R, Land SR, et al. Phase II trial of short-course CHOP-R followed by 90Y-tositumomab tixetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008;14:7088–94.
29. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase I/2 study of fractionated [131I]rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113:1412–21.
30. Illidge T, Du Y. When is a predose a dose too much? Blood. 2009;113:6034–5.
31. Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated 90Y-tositumomab tixetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNI criteria. J Clin Oncol. 2014;32:212–8.
32. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood. 2009;113:3891–5.
33. Witzig TE, Tomblin MB, Misleah JG, Kio EA, Sharkey RM, et al. Anti-CD22 90Y-epatuzumab tetracten combined with anti-CD20 veltuzumab: a phase 1 study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014;99(11):1378–45.
34. Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra Hidde, et al. Prospects for dual-targeted antibody/radioantibody therapy. Blood. 2008;112:4579–86.
35. van Dongen GA, Huisman MC, Boellaard R, Hendrikse N, Windhorst A, Visser G, et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to apply? J Nucl Med Mol Imaging. 2014. [Epub ahead of print]